Gyre Therapeutics
GYRE
78 hedge funds and large institutions have $60.6M invested in Gyre Therapeutics in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 10 closing their positions.
7,625% more call options, than puts
Call options by funds: $309K | Put options by funds: $4K
65% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 20
0.1% more ownership
Funds ownership: 8.42% → 8.52% (+0.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 79 → 78 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
26% less capital invested
Capital invested by funds: $81.8M → $60.6M (-$21.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.51M |
| 2 |
BlackRock
New York
|
+$994K |
| 3 |
Renaissance Technologies
New York
|
+$878K |
| 4 |
Goldman Sachs
New York
|
+$546K |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$280K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.28M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$1.05M |
| 4 |
Millennium Management
New York
|
-$1.01M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$888K |
GYRE Hedge Fund Activity: Q3 2020 in Review
78 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2020, worth a combined $60.6M — down 26% from $81.8M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of GYRE and 9 opened new positions — a net loss of 1 holder — while 20 trimmed existing stakes and 33 added.
The largest buyer was Stonepine Capital Management, adding an estimated $4.51M. The largest seller was Citadel Advisors, cutting an estimated $2M.
- 78 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2020, down from 79 in Q2 2020.
- Funds reported $60.6M of Gyre Therapeutics stock for Q3 2020, down 26% quarter-over-quarter.
- 9 funds opened new Gyre Therapeutics positions in Q3 2020 and 10 closed out, a net change of -1 holder.
- The largest Gyre Therapeutics buyer in Q3 2020 was Stonepine Capital Management, an estimated $4.51M added.
- The largest Gyre Therapeutics seller in Q3 2020 was Citadel Advisors, an estimated $2M sold.
Based on aggregated 13F filings for Q3 2020.